Leerink Swann Initiates Fate Therapeutics With Outperform

Leerink Swann initiated coverage on Fate Therapeutics Inc (NASDAQ: FATE) with a Outperform rating.

The target price for Fate Therapeutics is set to $10.

Fate Therapeutics shares have dropped 6.71 percent over the past 52 weeks, while the S&P 500 index has surged 9.48 percent in the same period.

Fate Therapeutics' shares rose 1.92 percent to $6.38 in pre-market trading.